NYSE American - Delayed Quote USD

Can-Fite BioPharma Ltd. (CANF)

Compare

1.3980

-0.0120

(-0.85%)

At close: April 10 at 3:59:54 PM EDT

1.3500

-0.05

(-3.43%)

After hours: April 10 at 5:05:01 PM EDT

bioAffinity Technologies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FLORIDA / ACCESS Newswire / March 28, 2025 / RedChip Companies will air interviews with bioAffinity Technologies, Inc. (Nasdaq:BIAF) and Can-Fite BioPharma Ltd. (NYSE American:CANF) on the RedChip Small Stocks, Big Money™ show, a sponsored ...

ACCESS Newswire 13 days ago

CANF
-0.85%
BIAF

BIAFW
Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol

The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugs Ramat Gan, Israel, March 24, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that it initiated a pivotal phase 3 psoriasis study of its oral drug Piclidenoson with the U.S. Food and Drug Administration (FDA) and the

GlobeNewswire 17 days ago

CANF
-0.85%
Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market

Can-Fite’s upfront and royalties on sales upon regulatory approval of Piclidenoson for veterinary use, is projected to be $325 million in the aggregate over the next decade assuming a 2029 launch Ramat Gan, Israel, March 20, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that its veterinary partner Vetbiolix is in

GlobeNewswire 21 days ago

CANF
-0.85%
Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson

FDA & EMA approvals for rare genetic diseases are fast and require clinical studies with small number of patients Ramat Gan, Israel, March 19, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that a Phase II design is completed and preparatory work is undergoing for the initiation of clinical study in the rare gene

GlobeNewswire 22 days ago

CANF
-0.85%
Can-Fite: FDA Approved Compassionate Use Treatment with Namodenoson in a Pancreatic Cancer Patient

Ramat Gan, Israel, March 18, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that it received a single FDA approval for the compassionate use treatment of a U.S. based pancreatic cancer patient with its anti-cancer drug Namodenoson. Compassionate use is the term used when a physician is requesting for a single pati

GlobeNewswire 23 days ago

CANF
-0.85%
Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits

Unlike chemotherapy with its known toxicity towards normal body systems, Namodenoson provides protective effects Ramat Gan, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that the European Society of Medicine Journal published an innovative article titled: “The Neuro- Cardio- and Hepato- Protecti

GlobeNewswire last month

CANF
-0.85%
Disappearance of Decompensated Liver Cirrhosis Episodes After Treatment with Can-Fite's Namodenoson

Liver cirrhosis treatment market is estimated to reach approximately $15 billion in the U.S. by 2030 Ramat Gan, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced a significant clinical development: the disappearance of episodes of decompensated liver cirrhosis following treatment with Namodenoson und

GlobeNewswire last month

CANF
-0.85%
Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on February 25

RAMAT GAN, Israel, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, invites investors to a webinar on Tuesday, February 25, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Can-Fite Chief Executive Officer Motti Farbstein and Executive Chairperson and Chief Scientific Officer Dr. Pnin

GlobeNewswire last month

CANF
-0.85%
Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025

Ramat Gan, Israel, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that it will present at the BIO CEO & Investor Conference, taking place February 10-11, 2025, in New York City. Presentation Details: Event: BIO CEO & Investor Conference 2025Date & Time: February 10, 2025, at 3:45 pm ESTLocation: New York

GlobeNewswire 2 months ago

CANF
-0.85%
Can-Fite BioPharma secures US patent for Namodenoson

To be issued in February 2025, the patent will expire in 2042.

Pharmaceutical Technology 2 months ago

CANF
-0.85%
US Patent Office Granted Can-Fite Namodenoson Patent for Use as anti-Obesity Drug

The Namodenoson oral drug is well positioned in the field of anti-obesity agents due to its activity and favorable safety profile Ramat Gan, Israel, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that its lead drug candidate Namodenoson was granted a patent for its use as an anti-obesity drug by the US p

GlobeNewswire 2 months ago

CANF
-0.85%
CanFite Biopharma (CANF) Upgraded to Strong Buy: Here's What You Should Know

CanFite Biopharma (CANF) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks 2 months ago

CANF
-0.85%
Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite’s anti-Cancer Drug Namodenoson

Can-Fite’s data will be presented at the 2025 ASCO Gastrointestinal Cancers Symposium Can-Fite enrolls patients for its pivotal Phase III advanced liver cancer study Ramat Gan, Israel, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address Oncology and Inflammatory diseases, today announced that its work titled “The Liver Protective Effect of the anti-Cancer Drug C

GlobeNewswire 3 months ago

CANF
-0.85%
Bears are Losing Control Over CanFite Biopharma (CANF), Here's Why It's a 'Buy' Now

CanFite Biopharma (CANF) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Zacks 3 months ago

CANF
-0.85%
8 Years Survival with Complete Cure for a Patient with Advanced Liver Cancer Being Treated with Can-Fite’s Namodenoson Drug

RAMAT GAN, Israel, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, announced today that a patient currently treated with Namodenoson in a compassionate use program in Can-Fite’s Phase II Liver Cancer Study has an overall survival time of 8 years with a complete response. The patient, who suffered from advanced liver can

GlobeNewswire 4 months ago

CANF
-0.85%
60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FL / ACCESSWIRE / November 22, 2024 / RedChip Companies will air interviews with 60 Degrees Pharmaceuticals, Inc. (Nasdaq:SXTP) and Can-Fite BioPharma Ltd. (NYSE American:CANF)(TASE:CANF) on the RedChip Small Stocks, Big Money™ show, a sponsored ...

ACCESS Newswire 4 months ago

CANF
-0.85%
SXTP

SXTPW
Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial

Orphan Drug Designation has been granted lately by US FDA RAMAT GAN, Israel, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announces the dosing of the first patient in the Phase IIa clinical trial in patients with advanced pancreatic adenocarcinoma (NCT06387342). “We are excited to have the first patient enrolle

GlobeNewswire 4 months ago

CANF
-0.85%
Can-Fite BioPharma Secures Australian Patent for Obesity Drug

Can-Fite BioPharma (CANF) has released an update. Can-Fite BioPharma Ltd. has received a patent allowance in Australia for its oral anti-obesity drug Namodenoson, which has demonstrated a promising safety profile. The patent, valid until 2040, covers methods of treating obesity by increasing adiponectin hormone levels to reduce body fat. This advancement positions Can-Fite in the lucrative global obesity treatment market, valued at $12 billion in 2023. For further insights into CANF stock, check

TipRanks 5 months ago

CANF
-0.85%
Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia

Namodenoson is an oral drug with a proven favorable safety profile RAMAT GAN, Israel, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced an update related to the intellectual property (IP) status of its lead drug candidate Namodenoson, currently being developed for the treatment of Metabolic Dysfunction-asso

GlobeNewswire 5 months ago

CANF
-0.85%
Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson

Data Reported by Can-Fite Veterinary Partner Vetbiolix who already exercised its option for a full license deal worth $325M Ramat Gan, Israel, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that its veterinary partner Vetbiolix reported positive final results from the osteoarthritis multicenter clinical

GlobeNewswire 5 months ago

CANF
-0.85%

Performance Overview

Return	CANF	TA-125 (^TA125.TA)
YTD	-9.22%	+1.17%
1-Year	-38.14%	+23.60%
3-Year	-87.63%	+15.87%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Can-Fite BioPharma Ltd. (CANF)

bioAffinity Technologies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol

Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market

Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson

Can-Fite: FDA Approved Compassionate Use Treatment with Namodenoson in a Pancreatic Cancer Patient

Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits

Disappearance of Decompensated Liver Cirrhosis Episodes After Treatment with Can-Fite's Namodenoson

Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on February 25

Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025

Can-Fite BioPharma secures US patent for Namodenoson

US Patent Office Granted Can-Fite Namodenoson Patent for Use as anti-Obesity Drug

CanFite Biopharma (CANF) Upgraded to Strong Buy: Here's What You Should Know

Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite’s anti-Cancer Drug Namodenoson

Bears are Losing Control Over CanFite Biopharma (CANF), Here's Why It's a 'Buy' Now

8 Years Survival with Complete Cure for a Patient with Advanced Liver Cancer Being Treated with Can-Fite’s Namodenoson Drug

60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial

Can-Fite BioPharma Secures Australian Patent for Obesity Drug

Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia

Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson

Performance Overview